CONSTELLATION TECHNOLOGIES LIMITED — Board/Management Information 2002

Dec 10, 2002

ASX/MEDIA ANNOUNCEMENT

AGENIX APPOINTS CEO AS MANAGING DIRECTOR, FAREWELLS MARK CARNEGIF

11 December 2002

Brisbane-based biotechnology company Agenix Ltd [ASX:AGX] announced today that Mr Mark Carnegie has resigned from the Board of Directors. Mr Donald Home, Chief Executive Officer of Agenix, will take his place becoming Managing Director effective from tomorrow.

Mr Carnegie had been a director of Agenix since November 2000. "We thank Mark for the business acumen, enthusiasm and quidance he has contributed to Agenix over the past two years" said Mr Ravindran Govindan, Executive Chairman of Agenix.

"Don Home's 14 years experience as a Senior Executive for Abbott Laboratories has been extremely valuable since joining Agenix in June 2001. This change will place greater responsibility on Don in driving Agenix's commercialisation.

"During Mr Home's time as CEO, Agenix has achieved steady growth. It announced last month that group revenue for the first quarter of the financial year 2003 had increased by 12 per cent to \$9 million."

Agenix Limited [ASX:AGX] is a listed Australian-based company. It manufactures, distributes and markets human and veterinary diagnostic test kits, over-the-counter pharmaceuticals and infant care products via its fully-owned subsidiaries AGEN Biomedical and Milton Pharmaceuticals. Agenix focuses on developing a horizontally integrated product portfolio to service the needs of the acute phase thrombosis market. Agenix's lead candidate is its hightechnology ThromboView® blood clot-imaging project, which uses radiolabelled antibodies to locate blood clots in the body. This could revolutionise the \$US 3 billion annual clot diagnostic imaging market. Agenix employs 190 staff and sells its products to more than 50 countries. www.adenix.com